MedWatch

Genmab upgrades 2022 guidance

The company now targets revenue of DKK 12-13bn (USD 1.64-1.78bn) this year.

Photo: Joost Melis / Genmab / PR

Genmab upgrades its full-year guidance for 2022, now projecting annual revenue of DKK 12-13bn (USD 1.64-1.78bn) and operating profit totaling DKK 3.8-5.4bn (USD 521.3–740.8m).

The prior top-line prognosis was DKK 11-12bn (USD 1.5–1.6bn) and operating profit of DKK 3.2-4.8bn (USD 438.9–658.4m), Genmab informs in a statement Monday evening CEST.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs